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Abstract
Background: For most tubal ectopic pregnancies (EP) surgery is the treatment of first choice.
Whether surgical treatment should be performed conservatively (salpingostomy) or radically
(salpingectomy) in women wishing to preserve their reproductive capacity, is subject to debate.
Salpingostomy preserves the tube, but bears the risks of both persistent trophoblast and repeat
ipsilateral tubal EP. Salpingectomy, avoids these risks, but leaves only one tube for reproductive
capacity. This study aims to reveal the trade-off between both surgical options: whether the
potential advantage of salpingostomy, i.e. a better fertility prognosis as compared to salpingectomy,
outweighs the potential disadvantages, i.e. persistent trophoblast and an increased risk for a repeat
EP.
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Methods/Design:  International multi centre randomised controlled trial comparing
salpingostomy versus salpingectomy in women with a tubal EP without contra lateral tubal
pathology. Hemodynamically stable women with a presumptive diagnosis of tubal EP, scheduled for
surgery, are eligible for inclusion. Patients pregnant after in vitro fertilisation (IVF) and/or known
documented tubal pathology are excluded. At surgery, a tubal EP must be confirmed. Only women
with a tubal EP amenable to both interventions and a healthy contra lateral tube are included.
Salpingostomy and salpingectomy are performed according to standard procedures of participating
hospitals. Up to 36 months after surgery, women will be contacted to assess their fertility status at
six months intervals starting form the day of the operation.
The primary outcome measure is the occurrence of spontaneous viable intra uterine pregnancy.
Secondary outcome measures are persistent trophoblast, repeat EP, all pregnancies including those
resulting from IVF and financial costs. The analysis will be performed according to the intention to
treat principle. A cost-effectiveness analysis will be performed within a decision analysis framework,
based on costs per live birth, including IVF treatment whenever a spontaneous pregnancy does not
occur. Patients' preferences will be assessed using a discrete choice experiment.
Discussion:  This trial will provide evidence on the trade off between salpingostomy and
salpingectomy for tubal EP in view of the pros and cons of both interventions and will offer guidance
to clinicians in making the right treatment choice.
Trial registration: Current Controlled Trials ISRCTN37002267
Background
In the treatment of tubal ectopic pregnancy (EP), laparo-
scopic surgery remains the cornerstone of treatment [1].
In the absence of randomised data, the question as to
whether surgical treatment should be performed either
conservatively (salpingostomy) or radically (salpingec-
tomy) in women with desire for future pregnancy is sub-
ject to ongoing debate.
Since the first study demonstrated the potential effective-
ness of salpingostomy, this treatment has been compared
with salpingectomy in numerous non-randomised studies
[2]. Pooled data showed no beneficial effect of salpingos-
tomy on intra uterine pregnancy (IUP) whereas there is an
increased risk of repeat EP [3,4]. Based on these findings,
the Royal College of Obstetricians and Gynaecologists
guideline advises salpingectomy as the preferred standard
surgical approach for tubal EP [5]. However, there are
good reasons to question this advice. Interpretation of the
pooled data is troublesome since many of the original
studies failed to report essential details, e.g. time to preg-
nancy, presence of the desire for future pregnancy and
whether subsequent pregnancies occurred either sponta-
neously or after fertility treatment, such as in vitro fertili-
zation (IVF). Only a few non-randomised studies have
taken these matters into account and came to different
conclusions [6-11]; The IUP rates were higher and the
time to an IUP was shorter after salpingostomy compared
to salpingectomy. Especially in women with a history of
bilateral tubal pathology, salpingostomy offered better
IUP rates than salpingectomy, albeit at the cost of an
increased risk for repeat EP [6-8,10]. In women without a
history of tubal pathology this benefit was less clear and
also in these women there was an increased risk for repeat
EP [8]. In view of these data, we feel that the most effective
type of surgery for women with a tubal EP in the presence
of contra lateral tubal pathology with desire for future
pregnancy is salpingostomy. In women without contra
lateral tubal pathology, the most optimal surgical treat-
ment is currently unknown.
Objective
To study whether the potential advantage of salpingos-
tomy, i.e. a better fertility prognosis as compared to salp-
ingectomy, outweighs the potential disadvantages of this
treatment, i.e. persistent trophoblast and an increased risk
for repeat EP in women with a tubal EP without contra lat-
eral tubal pathology.
Methods
Participating centres
This study is an international multi centre randomised
controlled trial, originally in a Dutch-Swedish-British col-
laboration since October 1st, 2005. During the study
period, other centres were contacted to participate. Since
June 1st, 2006, a centre in North Carolina (USA) has
joined the collaboration.
Inclusion criteria
Hemodynamically stable women ≥ 18 years of age with a
presumptive diagnosis of tubal EP who are scheduled for
surgery, are eligible for the trial. Excluded are women
without desire for future pregnancy, patients pregnant
after IVF, patients with a pregnancy in a solitary tube andBMC Women's Health 2008, 8:11 http://www.biomedcentral.com/1472-6874/8/11
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those patients with a contra lateral tubal occlusion or hyd-
rosalpinx as documented earlier at hysterosalpingography
or laparoscopy or as found during surgery for the index
EP.
Ethical considerations
Approval for this study was obtained from the Medical
Ethical Committees of the Academic Medical Centre,
Amsterdam, The Netherlands, Sahlgrenska University
Hospital, Göteborg, Sweden, Kings Hospital, London,
UK, and Wake Forest University School of Medicine, Win-
ston-Salem, North Carolina, USA.A quality assessment
has been made and approved by three external referees,
experts from the field by the Netherlands Organization for
Health Research and Development (ZonMw).
In each patient fulfilling the inclusion criteria, written
informed consent is obtained before randomisation.
Women refusing participation are registered.
Randomisation
Randomisation is performed during surgery by accessing
a central internet-based randomisation program. Ran-
domisation is stratified for hospital, patient's age and his-
tory of tubal pathology (i.e., previous EP, previous tubal
surgery, and previous pelvic inflammatory disease).
Interventions
At surgery, which can either be performed laparoscopi-
cally or by laparotomy, the presence of a tubal EP must be
confirmed. Patients with tubal rupture will be excluded,
whenever this interferes with the possibility to perform
salpingostomy. The surgeon will assess the status of the
contra lateral tube during the procedure. If, according to
the surgeon, the condition of the contra lateral tube
renders future pregnancy unlikely in case the patient will
be randomised to salpingectomy for the index tubal preg-
nancy (i.e., hydrosalpinx, severe peritubal adhesions, mal-
formations, or other reasons), the patient is excluded.
Thus, only patients with a tubal EP that allows both inter-
ventions, and a contra lateral tube that would allow spon-
taneous conception in case of salpingectomy, are being
included in the study.
Whenever necessary, laparoscopy may be converted to
open surgery. Salpingostomy is performed following local
procedural standards used in the participating hospitals.
Preferably linear salpingostomy is performed, but other
methods are allowed. Whenever necessary, salpingostomy
may be converted to salpingectomy, e.g. in case of uncon-
trollable bleeding. A complete salpingectomy is per-
formed following local procedural standards of the
participating hospitals. All methods of treatment are reg-
istered in the Case Record Form.
Follow-up
Short term follow-up
Complications during the immediate postoperative
period are registered in the Case Record Form. To identify
persistent trophoblast in both treatment groups, serum
hCG is measured postoperatively on a weekly basis until
undetectable in both treatment arms to identify persistent
trophoblast. Serum hCG concentrations are expressed in
IU/L (conversion factor to SI unit, 1.00 according to the
World Health Organization Third International Standard
75/537). Persistent trophoblast is defined as post opera-
tive rising or plateauing serum hCG concentrations [12].
Long term follow-up
To assess fertility after the operation of the index tubal EP,
the patients are contacted by means of a questionnaire,
every six months for a period of 36 months. The question-
naire focuses on the presence of a desire for pregnancy,
unprotected sexual intercourse with a chance of spontane-
ous conception, contraceptive use, infertility treatment,
and the occurrence of any pregnancies and their outcomes
(Figure 1).
Outcome measures
Primary outcome measure
The primary outcome measure is the time to the occur-
rence of a spontaneous viable IUP. A viable IUP is defined
as a pregnancy visible at ultrasound at a gestational age of
≥ 12 weeks with fetal cardiac activity, or the delivery of a
child. If an IUP does not occur, follow-up ends on the day
of the last consultation.
Secondary outcome measures
Secondary outcome measures are persistent trophoblast,
repeat EP, all pregnancies including those resulting from
IVF and financial costs. Patients' preferences will also be
assessed.
Persistent trophoblast is defined as rising or plateauing
serum hCG concentrations postoperatively and is prima-
rily treated with systemic methotrexate (MTX) or other-
wise if necessary [12].
Repeat EP is defined as a visible EP at ultrasound, a preg-
nancy of unknown location (PUL) with a serum hCG
above the discriminatory zone or as a persisting PUL for
which surgical or medical treatment with MTX is installed.
Failing PULs, which are managed expectantly with an une-
ventful decline of serum hCG to an undetectable level,
will be reported separately and are not considered repeat
EPs. The date of occurrence of an EP or failing PUL will
also be determined from the first day of the last menstrual
period.BMC Women's Health 2008, 8:11 http://www.biomedcentral.com/1472-6874/8/11
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Flowchart ESEP study Figure 1
Flowchart ESEP study.
 Inclusion ESEP Study:
 • Age ≥ 18 yrs
 • Clinical suspicion of tubal pregnancy
 • Scheduled for surgery
Informed Consent
Randomisation
No
Exclusion before surgery
• Signs of shock
• Pregnant after IVF-ET
• Known bilateral tubal factor, by HSG or 
laparoscopy
• Previous salpingectomy
Salpingo(s)tomy      Salpingectomy
 • Pre-operative serum hCG  
 • Laparoscopy/laparotomy
 • Conversion to salpingectomy
 • Complications
 • Persistent trophoblast?
Follow-up 6,12, 18, 24, 30, 36
months after index tubal pregnancy
 • Desire future pregnancy
• Spontanous  intra uterine pregnancy 
 • Repeat ectopic pregnancy
Log registration
Surgery
Exclusion during surgery
• No tubal pregnancy
• Salpingo(s)tomy not possible 
• Severe damage of contra lateral tube  
(hydrosalpinx, peri tubal adhesions, or 
malformations interfering with pregnancy) 
Registration 
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Costs are expressed as direct costs, for which data on both
costs and used resources are assessed in a subset of the par-
ticipating hospitals.
Patients' preferences are assessed by an online question-
naire using a discrete choice experiment (DCE) based on
characteristics of both interventions and will be compared
with a control group, recruited among women visiting the
infertility clinics in a subset of the participating hospitals.
Statistical analysis
The analysis is performed according to the intention to treat
principle. Short term outcome measures are expressed in
RR and their 95% confidence intervals.
Future fertility is assessed by means of life table analysis.
Kaplan-Meier curves are constructed, estimating the
cumulative probability of spontaneous IUP and repeat EP
over time. The assessment of fertility status is censored for
those periods when women used contraceptives or did
not have sexual intercourse. In case a spontaneous viable
IUP does not occur, follow up ends at the last date of con-
sultation, or at the moment when either IVF or tubal sur-
gery is performed. Spontaneous conceptions that occur
after failed IVF treatment will be registered, but these preg-
nancies will not be considered as endpoint in the analysis.
The log-rank test is used to test differences between the
Kaplan-Meier curves for statistical significance. The differ-
ences between both treatment modalities are expressed as
a FRR with 95% confidence interval, calculated through
Cox proportional hazard analysis.
A cost-effectiveness analysis will be performed within a
decision analysis framework, based on outcome of costs
per live birth, including IVF programs in case a spontane-
ous pregnancy does not occur.
Patient's preferences will be analysed by differences in
outcome of the DCE.
Sample size
The IUP rate after salpingectomy is assumed to be 40%
after 36 months and the median time to pregnancy in this
group is 1.4 year [8]. We consider an increase of the IUP
rate by 10–15% after salpingostomy compared to salp-
ingectomy clinically relevant to overcome the disadvan-
tages of persistent trophoblast and repeat EP. In order to
prove a reduction of the median time to pregnancy from
1.4 year to 1 year, 225 patients in each group are required
(significance level of 5%, a power of 80%, and 5% loss to
follow up in both groups, 2-sided test).
Interim analysis
An interim analysis will be performed after the inclusion
of 150 women. This analysis will be done by an independ-
ent Data and Safety Monitoring Committee (DSMC) that
will not be aware of the allocation of treatment. The sta-
tistical analysis will be performed according to O'Brien
Fleming's rule. The decision to unblind treatment alloca-
tion is at the discretion of the DSMC. The DSMC provides
a recommendation in a report to the trial coordinators.
The decision to terminate or continue the study will be
made in consultation with the participating centres.
Subgroup analyses
Pre conceived subgroup analyses are planned for age
(under and over 30 years), history of a previous EP, pre-
operative serum hCG-level (< 3,000 IU/l, 3,000–6,000
IU/l, and > 6,000 IU/l), and size of the ectopic mass (less
or more than 4 cm).
Discussion
In industrialized countries the incidence of EP is approxi-
mately 1 to 2% of all pregnancies [13-15]. Apart from the
immediate treatment burden and the major psychological
impact of an early pregnancy loss, there is also concern
about the effect on future fertility.
To date, there are no randomised controlled trials, which
have examined the potential benefits of performing salp-
ingostomy in women with no evidence of contra lateral
tubal damage as compared to salpingectomy. Despite this
lack of evidence, clinicians prefer a salpingectomy over a
salpingostomy in the presence of a healthy contra lateral
tube [16]. This preference is based on the small risk of
tubal bleeding in the immediate postoperative period, the
potential need for further treatment for persistent tro-
phoblast and the possibility of a repeat EP in the con-
served tube. Moreover, many clinicians prefer a
salpingectomy because they find this intervention easier
to perform and more quickly done than a salpingostomy.
Although short term costs are lower for salpingectomy, in
the long term it might be more costly because of the asso-
ciated fertility problems in case of unfulfilled child wish
[17]. As earlier demonstrated in a threshold analysis,
based on retrospective data, salpingostomy would already
be more cost-effective than salpingectomy followed by
three cycles of IVF when the increase in spontaneous IUP
exceeded a mere 2%, which corresponds with a FRR of
1.05 [18]. On the other hand, if salpingostomy would not
be better than salpingectomy, the number of prevented
cases of persistent trophoblast and repeat EP might very
well tip the balance, and lead to potential savings in the
other direction.
This randomised controlled trial aims to provide the final
evidence in the trade off between salpingostomy and salp-
ingectomy for tubal EP in view of the remaining uncer-BMC Women's Health 2008, 8:11 http://www.biomedcentral.com/1472-6874/8/11
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tainties of both interventions and will offer guidance to
clinicians in their decision making.
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